Trial Profile
A phase 1 study of SEL-403 in patients with pancreatic cancer
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 27 Aug 2018
Price :
$35
*
At a glance
- Drugs SEL-403 (Primary)
- Indications Mesothelioma
- Focus Adverse reactions
- 27 Aug 2018 New trial record
- 08 Aug 2018 According to a Selecta Biosciences media release, the company is working with the National Cancer Institute (NCI) to conduct this study.